As top court invalidates some gene patents, biotech has moved on

By Sharon Begley NEW YORK (Reuters) – The U.S. Supreme Court decision on Thursday to uphold patent protections for genetic material that has been changed in the laboratory but invalidate patents for purely natural DNA may seem like a partial setback for the biotech industry, but experts said it isn’t: the industry has already moved on. …